AllianceBernstein’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

AllianceBernstein’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,443	Closed	-$38.8K	–	3277
2023 Q1	$38.8K	Hold	1,443	–	–	﹤0.01%	3107
2022 Q4	$51.1K	Buy	1,443 +243	+20%	+$29.2K	﹤0.01%	3172
2022 Q3	$271K	Buy	1,200 +93	+8%	+$22.9K	﹤0.01%	2909
2022 Q2	$209K	Buy	1,107 +127	+13%	+$25.6K	﹤0.01%	3012
2022 Q1	$244K	Hold	980	–	–	﹤0.01%	2942
2021 Q4	$153K	Sell	980 -63	-6%	-$12.2K	﹤0.01%	3132
2021 Q3	$209K	Hold	1,043	–	–	﹤0.01%	3077
2021 Q2	$267K	Buy	1,043 +43	+4%	+$10.7K	﹤0.01%	3058
2021 Q1	$266K	Hold	1,000	–	–	﹤0.01%	2957
2020 Q4	$369K	Hold	1,000	–	–	﹤0.01%	2747
2020 Q3	$244K	Hold	1,000	–	–	﹤0.01%	2903
2020 Q2	$288K	Buy	1,000 +357	+56%	+$105K	﹤0.01%	2891
2020 Q1	$131K	Buy	643 +300	+87%	+$95.6K	﹤0.01%	2906
2019 Q4	$153K	Hold	343	–	–	﹤0.01%	2978
2019 Q3	$106K	Buy	+343	New	+$111K	﹤0.01%	3073

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

AllianceBernstein's EIGR Position: Q2 2023 in Review

AllianceBernstein sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 1,443 shares — an estimated $38.8K sold.

AllianceBernstein first reported a position in EIGR in Q3 2019 and held it in 15 quarters. The position peaked at $369K in Q4 2020. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

AllianceBernstein reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
AllianceBernstein sold 1,443 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $38.8K.
AllianceBernstein first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 15 quarters.
AllianceBernstein's Eiger BioPharmaceuticals, Inc. position peaked at $369K in Q4 2020.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.